2020
Updating insights into rosiglitazone and cardiovascular risk through shared data: individual patient and summary level meta-analyses
Wallach JD, Wang K, Zhang AD, Cheng D, Grossetta Nardini HK, Lin H, Bracken MB, Desai M, Krumholz HM, Ross JS. Updating insights into rosiglitazone and cardiovascular risk through shared data: individual patient and summary level meta-analyses. The BMJ 2020, 368: l7078. PMID: 32024657, PMCID: PMC7190063, DOI: 10.1136/bmj.l7078.Peer-Reviewed Original ResearchConceptsIndividual patient-level dataCardiovascular related deathsCardiovascular riskMyocardial infarctionRelated deathsSummary-level dataHeart failureOdds ratioSystematic reviewIncreased cardiovascular riskMore myocardial infarctionsHeart failure eventsCochrane Central RegistryAcute myocardial infarctionMyocardial infarction eventsPatient-level dataRandom-effects modelWeb of ScienceAnalysis of trialsEligible trialsComposite outcomeAdverse eventsContinuity correctionControlled TrialsRosiglitazone treatment
2017
Inferior Vena Cava Filters to Prevent Pulmonary Embolism Systematic Review and Meta-Analysis
Bikdeli B, Chatterjee S, Desai NR, Kirtane AJ, Desai MM, Bracken MB, Spencer FA, Monreal M, Goldhaber SZ, Krumholz HM. Inferior Vena Cava Filters to Prevent Pulmonary Embolism Systematic Review and Meta-Analysis. Journal Of The American College Of Cardiology 2017, 70: 1587-1597. PMID: 28935036, PMCID: PMC8412839, DOI: 10.1016/j.jacc.2017.07.775.Peer-Reviewed Original ResearchConceptsDeep vein thrombosisSubsequent pulmonary embolismInferior vena cava filterPulmonary embolismVena cava filtersIVC filtersCause mortalityOdds ratioCava filtersSystematic reviewSubsequent deep vein thrombosisInverse variance fixed-effect modelRisk of PECochrane Central RegisterQuality of evidenceFixed-effects modelCentral RegisterVein thrombosisControlled TrialsOverall mortalityObservational studyMAIN OUTCOMEPrimary analysisMeta-AnalysisMortality
1997
Administration of methylprednisolone for 24 or 48 hours or tirilazad mesylate for 48 hours in the treatment of acute spinal cord injury. Results of the Third National Acute Spinal Cord Injury Randomized Controlled Trial. National Acute Spinal Cord Injury Study.
Bracken MB, Shepard MJ, Holford TR, Leo-Summers L, Aldrich EF, Fazl M, Fehlings M, Herr DL, Hitchon PW, Marshall LF, Nockels RP, Pascale V, Perot PL, Piepmeier J, Sonntag VK, Wagner F, Wilberger JE, Winn HR, Young W. Administration of methylprednisolone for 24 or 48 hours or tirilazad mesylate for 48 hours in the treatment of acute spinal cord injury. Results of the Third National Acute Spinal Cord Injury Randomized Controlled Trial. National Acute Spinal Cord Injury Study. JAMA 1997, 277: 1597-604. PMID: 9168289, DOI: 10.1001/jama.277.20.1597.Peer-Reviewed Original ResearchConceptsAcute spinal cord injurySpinal cord injuryNational Acute Spinal Cord Injury StudyFunctional Independence MeasureHours of injuryCord injuryTirilazad groupRegimen groupMethylprednisolone infusionAcute Spinal Cord Injury StudySpinal Cord Injury StudySpinal cord injury centerEfficacy of methylprednisoloneImproved motor recoveryMotor recovery rateAdministration of methylprednisoloneMotor function changesSteroid therapyMethylprednisolone groupSevere sepsisTirilazad mesylateMotor recoveryControlled TrialsInitial presentationIntravenous bolusAdministration of Methylprednisolone for 24 or 48 Hours or Tirilazad Mesylate for 48 Hours in the Treatment of Acute Spinal Cord Injury: Results of the Third National Acute Spinal Cord Injury Randomized Controlled Trial
Bracken M, Shepard M, Holford T, Leo-Summers L, Aldrich E, Fazl M, Fehlings M, Herr D, Hitchon P, Marshall L, Nockels R, Pascale V, Perot P, Piepmeier J, Sonntag V, Wagner F, Wilberger J, Winn H, Young W. Administration of Methylprednisolone for 24 or 48 Hours or Tirilazad Mesylate for 48 Hours in the Treatment of Acute Spinal Cord Injury: Results of the Third National Acute Spinal Cord Injury Randomized Controlled Trial. JAMA 1997, 277: 1597-1604. DOI: 10.1001/jama.1997.03540440031029.Peer-Reviewed Original ResearchAcute spinal cord injurySpinal cord injuryNational Acute Spinal Cord Injury StudyFunctional Independence MeasureHours of injuryCord injuryTirilazad groupRegimen groupTirilazad mesylateMethylprednisolone infusionAcute Spinal Cord Injury StudySpinal Cord Injury StudySpinal cord injury centerEfficacy of methylprednisoloneImproved motor recoveryMotor recovery rateAdministration of methylprednisoloneMotor function changesSteroid therapyMethylprednisolone groupSevere sepsisMotor recoveryControlled TrialsInitial presentationIntravenous bolus
1991
A Randomized, Controlled Trial of Methylprednisolone or Naloxone in the Treatment of Acute Spinal-Cord Injury
BRACKEN M, SHEPARD M, COLLINS W, HOLFORD T, YOUNG W, BASKIN D, EISENBERG H, FLAMM E, LEOSUMMERS L, MAROON J, MARSHALL L, PEROT P, PIEPMEIER J, SONNTAG V, WAGNER F, WILBERGER J, WINN H. A Randomized, Controlled Trial of Methylprednisolone or Naloxone in the Treatment of Acute Spinal-Cord Injury. Survey Of Anesthesiology 1991, 35: 50. DOI: 10.1097/00132586-199102000-00048.Peer-Reviewed Original Research
1990
A Randomized, Controlled Trial of Methylprednisolone or Naloxone in the Treatment of Acute Spinal-Cord Injury
Bracken M, Shepard M, Collins W, Holford T, Young W, Baskin D, Eisenberg H, Flamm E, Leo-Summers L, Maroon J, Marshall L, Perot P, Piepmeier J, Sonntag V, Wagner F, Wilberger J, Winn H. A Randomized, Controlled Trial of Methylprednisolone or Naloxone in the Treatment of Acute Spinal-Cord Injury. New England Journal Of Medicine 1990, 322: 1405-1411. PMID: 2278545, DOI: 10.1056/nejm199005173222001.Peer-Reviewed Original ResearchConceptsAcute spinal cord injurySpinal cord injuryNeurologic recoverySafety of methylprednisoloneSystematic neurological examinationPlacebo-controlled trialHours of injuryMajor morbidityNeurologic outcomeControlled TrialsNeurological examinationIncomplete lesionsMotor functionMethylprednisoloneNaloxonePatientsBody weightSensory functionInjuryPlaceboInfusionBolusEffective remainsTreatmentDose